Vector Science and Therapeutics (TSXV:PAIN) Other Stockholders Equity: C$0.16 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:PAIN Vector Science and Therapeutics Corp TSXV:PAIN
14 GF Score
Price C$1.55
View Full Analysis

What is Vector Science and Therapeutics Other Stockholders Equity?

Vector Science and Therapeutics TSXV:PAIN -4.32% 14 Other Stockholders Equity is C$0.16 Mil as of Feb. 2026. GuruFocus rates TSXV:PAIN with a GF Score™ of 14/100.

Vector Science and Therapeutics's Other Stockholders Equity for the quarter that ended in Feb. 2026 was C$0.16 Mil.

Vector Science and Therapeutics's quarterly Other Stockholders Equity increased from Aug. 2025 (C$0.16 Mil) to Nov. 2025 (C$0.16 Mil) but then declined from Nov. 2025 (C$0.16 Mil) to Feb. 2026 (C$0.16 Mil).

Vector Science and Therapeutics's annual Other Stockholders Equity stayed the same from . 20 (C$0.00 Mil) to Aug. 2024 (C$0.00 Mil) but then increased from Aug. 2024 (C$0.00 Mil) to Aug. 2025 (C$0.16 Mil).

Vector Science and Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Vector Science and Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vector Science and Therapeutics Other Stockholders Equity Chart

Vector Science and Therapeutics Annual Data
Trend Aug24 Aug25
Other Stockholders Equity
0.00 0.16

Vector Science and Therapeutics Quarterly Data
Aug24 Nov24 Aug25 Nov25 Feb26
Other Stockholders Equity 0.00 0.00 0.16 0.16 0.16
TSXV:PAIN
14GF Score
Vector Science and Therapeutics Corp TSXV:PAIN
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vector Science and Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of C$0.16 Mil mean?
Vector Science and Therapeutics (TSXV:PAIN) has a Other Stockholders Equity of C$0.16 Mil as of Feb. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Vector Science and Therapeutics and its competitors.
Is Vector Science and Therapeutics' Other Stockholders Equity too high?
Vector Science and Therapeutics' current Other Stockholders Equity is C$0.16 Mil. Overall, Vector Science and Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Vector Science and Therapeutics' Other Stockholders Equity compare to ABT and SYK?
Vector Science and Therapeutics' Other Stockholders Equity of C$0.16 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Devices & Instruments company?
A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Vector Science and Therapeutics and its competitors. Vector Science and Therapeutics's current Other Stockholders Equity is C$0.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vector Science and Therapeutics stock overvalued right now?
Vector Science and Therapeutics (TSXV:PAIN) has a current Other Stockholders Equity of C$0.16 Mil. The current Other Stockholders Equity is C$0.16 Mil. Vector Science and Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Vector Science and Therapeutics (TSXV:PAIN), the current Other Stockholders Equity is C$0.16 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vector Science and Therapeutics Business Description

Vector Science and Therapeutics Corp develops novel biomechanical devices and active transdermal drug and peptide delivery platforms to equip clinicians with non-systemic, localized interventions targeting a broad cross-section of diseases and conditions where systemic delivery of interventions compromises the therapeutic effect or introduces unacceptable harm.
14GF Score

Get the complete analysis for TSXV:PAIN

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$1.55
Price